Shares of Moderna have rebounded sharply this year as investors look beyond the company’s COVID-19 legacy and toward a broader mRNA pipeline in respiratory vaccines and oncology. The momentum comes alongside evidence of near-term product diversification, plus upcoming regulatory and clinical milestones that could shape expectations for the company’s commercial turnaround.
Key takeaways
- Price move: Moderna shares are up more than 100% year to date.
- Catalyst: Investors are reacting to renewed growth signals, including a strong first-quarter revenue increase and progress in mRNA vaccine development.
- What’s driving sentiment: The company is advancing respiratory candidates such as mFlusiva and a COVID-19/flu combination vaccine, while also pushing into cancer vaccine development through its personalized oncology platform.
- Key implication: The stock’s premium valuation appears to hinge on whether clinical readouts and FDA decisions translate into durable revenue beyond COVID-19.
What drove the move
Moderna’s resurgence has been linked to efforts to rebuild revenue streams after COVID-19 vaccine sales declined. According to the company’s results cited in the article, Moderna reported first-quarter revenue of $389 million, representing a 260% year-over-year increase. That growth has helped reinforce the view that the platform is capable of supporting new commercial cycles.
Investors are also weighing progress in respiratory vaccines, where regulatory timelines may provide clearer direction on potential adoption. The article points to mFlusiva, Moderna’s investigational mRNA-based seasonal influenza vaccine, which the FDA is evaluating with a target action date of Aug. 5. It also notes that advisory committee materials were described as highly positive, while acknowledging the panel had questioned the study methodology—without identifying major efficacy deficiencies.
Respiratory expansion and combination vaccine momentum
Moderna’s strategy includes not only stand-alone influenza protection but also combination approaches designed to improve convenience for patients and providers. The article says Moderna is developing a flu-plus-COVID-19 combination vaccine, and that phase 3 results outperformed the current stand-alone vaccines for both viruses.
In Europe, the article adds that the European Commission approved the combination vaccine, called mCOMBRIAX, targeting adults aged 50 and older. The stated goal is to reduce logistical friction by enabling dual immunization during a single appointment, which could support uptake for both components.
Oncology as the longer-term re-rating lever
While respiratory catalysts may influence nearer-term timelines, the larger valuation narrative in the article centers on oncology. Moderna is developing an individualized cancer vaccine in partnership with Merck, referred to as intismeran autogene (mRNA-4157). The approach uses mRNA to instruct a patient’s immune system to target mutations found on tumor cells.
The article cites five-year phase 2 data presented in January for patients with high-risk melanoma, reported as showing sustained efficacy when combined with Merck’s Keytruda. It further notes that pivotal phase 3 data readouts are expected later this year, a timing that could determine whether investors start to underwrite oncology revenue potential more aggressively.
Financial runway and operational scaling
Beyond product development, the article describes Moderna’s preparations for broader commercialization. It says Moderna is positioning for up to three new product launches between 2027 and 2028, spanning infectious disease programs (including a norovirus vaccine), intismeran, and treatments for rare diseases such as propionic acidemia.
The company also appears to be reshaping leadership to support global launch execution, according to the article, which mentions the appointment of a veteran chief commercial officer. On the balance sheet, the article states Moderna had $7.5 billion in cash and little debt, supporting a multi-year runway and a goal of companywide breakeven by 2028.
Still, the article highlights that profitability remains a key watch item. In the first quarter, it reports an earnings per share loss of $3.40 versus a $2.52 loss in the first quarter of 2025. It also attributes results to a one-time $878 million litigation loss; excluding that item, adjusted EPS loss was reported as $1.18, compared with a $0.88 loss a year earlier. That framing suggests the market’s optimism depends on progress that goes beyond headline revenue growth.
What analysts and investors are likely focused on
Investors appear to be positioning Moderna as more than a single-product company, with the article describing the market’s interpretation of a premium price-to-sales valuation as effectively betting that upcoming clinical data and regulatory approvals will unlock commercial viability for a wider mRNA portfolio. The near-term question for investors is whether influenza and combination vaccine programs can convert trial momentum into approved products and steady demand.
For the medium to longer term, the key issue is whether oncology data can substantiate a meaningful pipeline payoff—particularly because the oncology program’s potential would represent a structural shift from Moderna’s COVID-19-driven revenue model.
Moderna’s next catalysts, as reflected in the article, include FDA decision-making around its seasonal flu vaccine candidate with a target action date of Aug. 5, as well as additional clinical developments later this year for its oncology program. Traders and long-term investors will also likely monitor quarterly updates for evidence that revenue growth is sustained without one-time items, alongside continued progress toward breakeven.
